InterPAD - DETAILS

Lapatinib, 231277-92-2, Lapatinib Ditosylate, Tykerb, GW572016, GW 572016, Lapatinib [INN], Lapatinib base, Tyverb, GW-572016, Lapatinib (INN), Lapatinib free base, N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)furan-2-yl)quinazolin-4-amine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine, N-{3-chloro-4-[(3-fluorophenyl)methoxy]phenyl}-6-(5-{[(2-methanesulfonylethyl)amino]methyl}furan-2-yl)quinazolin-4-amine, Lapatinib (free base), 231277-92-2 (free base), MFCD09264194, FMM, N-{3-CHLORO-4-[(3-FLUOROBENZYL)OXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]-4-QUINAZOLINAMINE, CHEMBL554, DTXSID7046675, CHEBI:49603, GW 282974X, 0VUA21238F, NSC745750, GSK-572016, GW-572016X, 1210608-87-9, N-[3-Chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]-2-furyl]quinazolin-4-amine, NCGC00167507-01, 913989-15-8, n-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-4-quinazolinamine, DTXCID5026675, 4-Quinazolinamine, N-(3-chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-, 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-, N-(3-chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine, N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-((2-methylsulfonylethylamino)methyl)-2-furyl)quinazolin-4-amine, N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)furan-2-yl]quinazolin-4-amine, GSK 572016, CAS-231277-92-2, GW-2016, Lapatinib [INN:BAN], C29H26ClFN4O4S, UNII-0VUA21238F, Lapatinib?, HSDB 8209, 1xkk, N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine, N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine, GSK572016, Lapatinib, Free base, nchembio866-comp20, Kinome_3684, Kinome_3685, Lapatinib base- Bio-X, LAPATINIB [MI], LAPATINIB [VANDF], LAPATINIB [WHO-DD], SCHEMBL8100, Lapatinib (GW572016), LAPATINIB [EMA EPAR], BDBM5445, cid_208908, GTPL5692, EX-A402, BCFGMOOMADDAQU-UHFFFAOYSA-N, BCPP000188, BCPP000189, HMS2089H10, HMS3244N06, HMS3244N10, HMS3244N14, HMS3744K11, Tykerb (TN) (Glaxo Smith Kline), BCP01874, Tox21_112505, NSC800780, AKOS005145766, Tox21_112505_1, AC-1314, BCP9000837, BCP9000838, CCG-270133, DB01259, NSC-745750, NSC-800780, SB16918, NCGC00167507-02, NCGC00167507-03, NCGC00167507-04, NCGC00167507-09, AS-14065, BC164610, HY-50898, N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-(5-((2-(methylsulfonyl)ethylamino)methyl)furan-2-yl)quinazolin-4-amine, N-(3-Chloro-4-{[(3-fluorophenyl)methyl]oxy}phenyl)-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furanyl]-4-quinazolinamine, AM20090641, FT-0659650, L0360, NS00003012, SW199101-5, A25184, D08108, EN300-117254, AB01273965-01, AB01273965-02, AB01273965-03, AB01273965_04, AB01273965_05, Q420323, Q-101353, SR-05000001472-1, BRD-K19687926-001-01-7, BRD-K19687926-379-02-5, 1092929-10-6, GW-2016;N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)furan-2-yl)quinazolin-4-amine;4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[(2-methanesulfonylethyl)amino]methyl]furan-2-yl]quinazoline, N-[3-chloro-4-(3-fluorobenzyloxy)phenyl]-6-[5-({[2-(methanesulfonyl)ethyl]amino}methyl)furan-2-yl]quinazolin-4-amine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]-2-furyl] quinazolin-4-amine, N-{3-chloro-4-[(3-fluoro-benzyl)oxy]phenyl}-6-[5-({2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine, N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methane sulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine, N-{3-Chloro-4[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methane sulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine

No.	Title	Href
1	Therapeutic Mechanism of Lapatinib Combined with Sulforaphane on Gastric Cancer. Evid Based Complement Alternat Med. 2021 Sep 18;2021:9933274. doi: 10.1155/2021/9933274.	`Click`
2	Combination of Lapatinib and luteolin enhances the therapeutic efficacy of Lapatinib on human breast cancer through the FOXO3a/NQO1 pathway. Biochem Biophys Res Commun. 2020 Oct 20;531(3):364-371. doi: 10.1016/j.bbrc.2020.07.049.	`Click`
3	Berberine reverses Lapatinib resistance of HER2-positive breast cancer cells by increasing the level of ROS. Cancer Biol Ther. 2016;17(9):925-934. doi:10.1080/15384047.2016.1210728	`Click`

No.

Title

Href

Therapeutic Mechanism of Lapatinib Combined with Sulforaphane on Gastric Cancer. Evid Based Complement Alternat Med. 2021 Sep 18;2021:9933274. doi: 10.1155/2021/9933274.

Click

Combination of Lapatinib and luteolin enhances the therapeutic efficacy of Lapatinib on human breast cancer through the FOXO3a/NQO1 pathway. Biochem Biophys Res Commun. 2020 Oct 20;531(3):364-371. doi: 10.1016/j.bbrc.2020.07.049.

Click

Berberine reverses Lapatinib resistance of HER2-positive breast cancer cells by increasing the level of ROS. Cancer Biol Ther. 2016;17(9):925-934. doi:10.1080/15384047.2016.1210728

Click

Name	Lapatinib
PubChem CID	208908
Molecular Weight	581.1g/mol
Synonyms	Lapatinib, 231277-92-2, Lapatinib Ditosylate, Tykerb, GW572016, GW 572016, Lapatinib [INN], Lapatinib base, Tyverb, GW-572016, Lapatinib (INN), Lapatinib free base, N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)furan-2-yl)quinazolin-4-amine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine, N-{3-chloro-4-[(3-fluorophenyl)methoxy]phenyl}-6-(5-{[(2-methanesulfonylethyl)amino]methyl}furan-2-yl)quinazolin-4-amine, Lapatinib (free base), 231277-92-2 (free base), MFCD09264194, FMM, N-{3-CHLORO-4-[(3-FLUOROBENZYL)OXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]-4-QUINAZOLINAMINE, CHEMBL554, DTXSID7046675, CHEBI:49603, GW 282974X, 0VUA21238F, NSC745750, GSK-572016, GW-572016X, 1210608-87-9, N-[3-Chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]-2-furyl]quinazolin-4-amine, NCGC00167507-01, 913989-15-8, n-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-4-quinazolinamine, DTXCID5026675, 4-Quinazolinamine, N-(3-chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-, 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-, N-(3-chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine, N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-((2-methylsulfonylethylamino)methyl)-2-furyl)quinazolin-4-amine, N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)furan-2-yl]quinazolin-4-amine, GSK 572016, CAS-231277-92-2, GW-2016, Lapatinib [INN:BAN], C29H26ClFN4O4S, UNII-0VUA21238F, Lapatinib?, HSDB 8209, 1xkk, N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine, N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine, GSK572016, Lapatinib, Free base, nchembio866-comp20, Kinome_3684, Kinome_3685, Lapatinib base- Bio-X, LAPATINIB [MI], LAPATINIB [VANDF], LAPATINIB [WHO-DD], SCHEMBL8100, Lapatinib (GW572016), LAPATINIB [EMA EPAR], BDBM5445, cid_208908, GTPL5692, EX-A402, BCFGMOOMADDAQU-UHFFFAOYSA-N, BCPP000188, BCPP000189, HMS2089H10, HMS3244N06, HMS3244N10, HMS3244N14, HMS3744K11, Tykerb (TN) (Glaxo Smith Kline), BCP01874, Tox21_112505, NSC800780, AKOS005145766, Tox21_112505_1, AC-1314, BCP9000837, BCP9000838, CCG-270133, DB01259, NSC-745750, NSC-800780, SB16918, NCGC00167507-02, NCGC00167507-03, NCGC00167507-04, NCGC00167507-09, AS-14065, BC164610, HY-50898, N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-(5-((2-(methylsulfonyl)ethylamino)methyl)furan-2-yl)quinazolin-4-amine, N-(3-Chloro-4-{[(3-fluorophenyl)methyl]oxy}phenyl)-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furanyl]-4-quinazolinamine, AM20090641, FT-0659650, L0360, NS00003012, SW199101-5, A25184, D08108, EN300-117254, AB01273965-01, AB01273965-02, AB01273965-03, AB01273965_04, AB01273965_05, Q420323, Q-101353, SR-05000001472-1, BRD-K19687926-001-01-7, BRD-K19687926-379-02-5, 1092929-10-6, GW-2016;N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)furan-2-yl)quinazolin-4-amine;4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[(2-methanesulfonylethyl)amino]methyl]furan-2-yl]quinazoline, N-[3-chloro-4-(3-fluorobenzyloxy)phenyl]-6-[5-({[2-(methanesulfonyl)ethyl]amino}methyl)furan-2-yl]quinazolin-4-amine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]-2-furyl] quinazolin-4-amine, N-{3-chloro-4-[(3-fluoro-benzyl)oxy]phenyl}-6-[5-({2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine, N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methane sulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine, N-{3-Chloro-4[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methane sulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine
Drug Type	Small molecule
Formula	C₂₉H₂₆ClFN₄O₄S
SMILES	CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl
InChI	1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)
InChIKey	BCFGMOOMADDAQU-UHFFFAOYSA-N
CAS Number	231277-92-2
ChEMBL ID	CHEMBL554
ChEBI ID	CHEBI:49603
TTD ID	D08CDI
Drug Bank ID	DB01259
KEGG ID	D08108
Toxicity	Organism	Test Type	Route(Dose)
	rat	LD50	intraperitoneal(165 mg/kg)
	mouse	LD50	intraperitoneal(254 mg/kg)
	rat	LD50	oral(322 mg/kg)
Structure			Download 2D MOL 3D MOL

Pair Name	Sulforaphane, Lapatinib
Partner Name	Sulforaphane
Disease Info	[ICD-11: 2B72]	Gastric cancer		Investigative
Biological Phenomena	Induction-->Blockade of cell cycle in G0/G1 phase
Gene Regulation	Down-regulation	Phosphorylation	AKT1	hsa207
	Down-regulation	Phosphorylation	ERBB2	hsa2064
	Down-regulation	Phosphorylation	MAPK1	hsa5594
In Vitro Model	SGC-7901	Human papillomavirus-related cervical adenocarcinoma	Homo sapiens (Human)	CVCL_0520
Result	Therapeutic Mechanism of Lapatinib Combined with Sulforaphane on Gastric Cancer

Pair Name	Luteolin, Lapatinib
Partner Name	Luteolin
Disease Info	[ICD-11: 2C60]	Breast cancer		Investigative
Gene Regulation	Up-regulation	Expression	BCL2L11	KEGG ID N.A.
	Up-regulation	Expression	CDKN1A	hsa1026
	Up-regulation	Expression	FOXO3	hsa2309
	Down-regulation	Phosphorylation	FOXO3	hsa2309
	Up-regulation	Expression	GADD45A	hsa1647
	Up-regulation	Expression	NQO1	hsa1728
In Vitro Model	SK-BR-3	Breast adenocarcinoma	Homo sapiens (Human)	CVCL_0033
	BT-474	Invasive breast carcinoma of no special type	Homo sapiens (Human)	CVCL_0179
	ZR-75-1	Invasive breast carcinoma of no special type	Homo sapiens (Human)	CVCL_0588
In Vivo Model	Mice were inoculated subcutaneously with 0.1 mL of cell suspension (ZR-75-1 and BT-474 cells).
Result	These data suggest that the combination of Lapatinib and luteolin may inhibit HER2 human breast cancer by significantly increasing the expression of FOXO3a and NQO1, two key genes in HER2 human breast cancer xenografts.

Pair Name	Berberine, Lapatinib
Partner Name	Berberine
Disease Info	[ICD-11: 2C60]	Breast cancer		Investigative
Biological Phenomena	Induction-->ROS generation
Gene Regulation	Down-regulation	Expression	MYC	hsa4609
	Down-regulation	Expression	NFE2L2	hsa4780
	Up-regulation	Expression	ROS1	hsa6098
In Vitro Model	BT-474LabR	Lapatinib-resistant breast adenocarcinoma	Homo sapiens (Human)	N.A.
In Vitro Model	AU-565LapR	Lapatinib-resistant breast adenocarcinoma	Homo sapiens (Human)	N.A.
Result	Berberine reverses Lapatinib resistance of HER2-positive breast cancer cells by increasing the level of ROS